| |
| |
|
| Insider
Information: |
Cline Darren S |
| Relationship: |
|
| City: |
Bothell |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
323,961 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,596,459 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
323,961 |
|
|
| Total
Value |
$16,596,459 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Seagen Inc |
SGEN |
EVP, Commercial |
2018-11-29 |
72,556 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
2018-06-21 |
0 |
Premium* |
|
|
Gw Pharmaceuticals Plc |
GWPH |
U.S. Chief Commercial ... |
2021-05-05 |
0 |
2019-05-28 |
0 |
Premium* |
|
|
Pyxis Oncology, Inc. |
PYXS |
|
2024-03-26 |
251,405 |
2021-12-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-05-09 |
4 |
OE |
$15.46 |
$145,790 |
D/D |
9,000 |
80,831 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-05-09 |
4 |
S |
$55.33 |
$497,983 |
D/D |
(9,000) |
71,831 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-06-12 |
4 |
S |
$68.90 |
$831,688 |
D/D |
(12,054) |
69,863 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-06-12 |
4 |
OE |
$15.46 |
$293,910 |
D/D |
10,086 |
79,831 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-08-27 |
4 |
AS |
$74.23 |
$355,125 |
D/D |
(4,784) |
65,079 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-08-30 |
4 |
A |
$0.00 |
$0 |
D/D |
18,644 |
83,723 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-11-21 |
4 |
S |
$56.68 |
$236,204 |
D/D |
(4,167) |
79,556 |
0 |
- |
|
| SGEN |
Seagen Inc |
EVP, Commercial |
• – – |
2018-11-29 |
4 |
S |
$62.88 |
$440,160 |
D/D |
(7,000) |
72,556 |
0 |
- |
|
| SGEN |
Seagen Inc |
Executive Vice President |
• – – |
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
46,113 |
0 |
- |
|
| SGEN |
Seagen Inc |
SVP, Commercial |
• – – |
2015-03-13 |
4 |
S |
$38.65 |
$289,876 |
D/D |
(7,500) |
33,135 |
0 |
- |
|
| SGEN |
Seagen Inc |
SVP, Commercial |
• – – |
2015-08-20 |
4 |
AS |
$42.02 |
$93,757 |
D/D |
(2,231) |
31,482 |
0 |
- |
|
| SGEN |
Seagen Inc |
SVP, Commercial |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
43,482 |
0 |
- |
|
| SGEN |
Seagen Inc |
SVP, Commercial |
• – – |
2015-11-11 |
4 |
S |
$45.68 |
$263,548 |
D/D |
(5,769) |
37,713 |
0 |
- |
|
| SGEN |
Seagen Inc |
SVP, CommercialOfficer |
• – – |
2015-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,635 |
|
- |
|
| GWPH |
Gw Pharmaceuticals Plc |
U.S. Chief Commercial Officer |
• – – |
2019-05-28 |
4 |
A |
$0.00 |
$38 |
D/D |
29,424 |
29,424 |
0 |
- |
|
| GWPH |
Gw Pharmaceuticals Plc |
U.S. Chief Commercial Officer |
• – – |
2020-05-28 |
4 |
A |
$10.54 |
$18,972 |
D/D |
1,800 |
5,556 |
0 |
- |
|
| GWPH |
Gw Pharmaceuticals Plc |
U.S. Chief Commercial Officer |
• – – |
2020-05-28 |
4 |
OE |
$0.00 |
$9 |
D/D |
7,356 |
7,356 |
0 |
- |
|
| GWPH |
Gw Pharmaceuticals Plc |
U.S. Chief Commercial Officer |
• – – |
2021-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,556) |
0 |
0 |
- |
|
43 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
